Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing prophylaxis of venous thromboembolism.

Alexander G G Turpie1

  • 1Hamilton Health Sciences-Hamilton General Hospital, Hamilton, Ontario, Canada.

Seminars in Thrombosis and Hemostasis
|June 20, 2002
PubMed
Summary

New antithrombotic therapies are needed for major orthopedic surgery patients. Fondaparinux, a selective factor Xa inhibitor, shows superior efficacy in preventing venous thromboembolism compared to existing treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2024
Same author

Country and health expenditure are major predictors of withholding anticoagulation in atrial fibrillation patients at high risk of stroke.

Open heart·2023
Same author

Comparing U.S. and Canadian treatment patterns on venous thromboembolism outcomes in the GARFIELD-VTE registry.

Thrombosis research·2023
Same author

Clinical Outcomes in Older Patients with Atrial Fibrillation: Insights from the GARFIELD-AF Registry.

The American journal of medicine·2023
Same author

Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials.

Thrombosis research·2023
Same author

Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry.

Diabetes, obesity & metabolism·2023

Area of Science:

  • Pharmacology
  • Hematology
  • Orthopedic Surgery

Background:

  • Thrombotic events are a significant complication in major orthopedic surgery, leading to high morbidity, mortality, and healthcare costs.
  • Current prophylactic therapies like unfractionated heparin, low-molecular-weight heparin, and warfarin are insufficient, with thrombotic events occurring at an unacceptably high rate.
  • The need for improved venous thromboembolism prophylaxis has driven the development of novel antithrombotics targeting specific hemostatic pathway steps.

Purpose of the Study:

  • To evaluate the efficacy and safety of fondaparinux, a novel selective factor Xa inhibitor, for thromboprophylaxis in major orthopedic surgery.
  • To compare fondaparinux with existing anticoagulant therapies in a large patient population undergoing major orthopedic procedures.

Main Methods:

  • Fondaparinux was evaluated through a comprehensive drug development program, including four large-scale Phase III clinical trials.
  • Over 7000 patients undergoing major orthopedic surgery were enrolled in these trials.

Main Results:

  • Fondaparinux demonstrated superior efficacy in preventing venous thromboembolism compared to existing treatments.
  • The drug received approval from the U.S. Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products.

Conclusions:

  • Fondaparinux represents a significant advancement in thromboprophylaxis for major orthopedic surgery.
  • Its superior efficacy may be attributed to selective factor Xa inhibition and predictable pharmacokinetics.

Related Experiment Videos